Nexalin Technology (NXL) EPS (Basic) Growth (1y) (2022 - 2026)
Nexalin Technology (NXL) EPS (Basic) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -18.87% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 13.56% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.90% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 97.93% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 92.23% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 114.97% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -29.95% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | 29.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.16% |
| Dec 31, 2025 | 52.77% |
| Sep 30, 2025 | 43.32% |
| Jun 30, 2025 | 41.29% |
| Mar 31, 2025 | -6.08% |
| Dec 31, 2024 | -189.25% |
| Sep 30, 2024 | 27.14% |
| Jun 30, 2024 | -51.79% |
| Mar 31, 2024 | -37.07% |
| Dec 31, 2023 | 22.60% |
| Sep 30, 2023 | -429.16% |
| Jun 30, 2023 | -22.79% |
| Mar 31, 2023 | -27.67% |
| Dec 31, 2022 | -12.96% |
| Sep 30, 2022 | 85.79% |